Seminars in Radiation Oncology
Volume 18, Issue 3 , Pages 152-160 , July 2008

Health Services Research

  • Mark S. Litwin, MD, MPH

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mark S. Litwin, MD, MPH, UCLA Department of Urology, Box 951738, Los Angeles, CA 90095-1738.

References 

  1. Andersen RM, Davidson PL. Improving access to care in America. In:  Anderson RM,  Rice TH,  Kominski GF editor. Changing the U.S. Health Care System. (ed 2). San Francisco, CA: Jossey-Bass; 2001;
  2. Andersen RM. Revisiting the behavioral model and access to medical care: Does it matter?. J Health Soc Behav. 1995;36:1–10
  3. Aday LA, Andersen RM. Equity of access to medical care: A conceptual and empirical overview. Med Care. 1981;19:4–27
  4. Griffiths V, Ahmed-Jushuf I, Cassell JA. Understanding access to genitourinary medicine services. Int J STD AIDS. 2004;15:587–589
  5. Fitzpatrick P, Corcoran N, Fitzpatrick JM. Prostate cancer: How aware is the public?. Br J Urol. 1998;82:43–48
  6. Kelley E, Moy E, Stryer D, et al. The national healthcare quality and disparities reports: An overview. Med Care. 2005;43(suppl):I3–I8
  7. Kelley E, Moy E, Dayton E. Health care quality and disparities: lessons from the first national reports. Med Care. 2005;43(suppl):I1–I2
  8. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90–94
  9. Lee TH. My insurance company won't pay for my prescription for Viagra without a letter from my doctor saying that I have been evaluated. As far as I know, I am the only one who can tell whether I have impotence. What does the insurance company want?. Harv Heart Lett. 1999;9:7
  10. Walsh DC, Connor E, Tracey LV, et al. Posthospital convalescence and return to work. Health Aff (Millwood). 1989;8:76–90
  11. Luz J, Green MS. Sickness absenteeism from work—A critical review of the literature. Public Health Rev. 1997;25:89–122
  12. Stewart WF, Ricci JA, Chee E, et al. Lost productive work time costs from health conditions in the United States: Results from the American Productivity Audit. J Occup Environ Med. 2003;45:1234–1246
  13. Munoz E, Mallett E, Gerold T, et al. Access and quality of care for urology patients under diagnostic related group reimbursement. J Urol. 1988;139:1256–1259
  14. Kahn KL, Rubenstein LV, Draper D, et al. The effects of the DRG-based prospective payment system on quality of care for hospitalized Medicare patients (An introduction to the series). JAMA. 1990;17264:1953–1955
  15. Munoz E, Goldstein J, Lory MH, et al. The DRG hospital payment system, surgical readmissions and cost containment. Am Surg. 1990;56:683–687
  16. Munoz E, Boiardo R, Mulloy K, et al. Economies of scale, physician volume for urology patients, and DRG prospective hospital payment system. Urology. 1990;36:471–476
  17. Munoz E, Mulloy K, Goldstein J, et al. Physicians' patient load per DRG, the consumption of hospital resources, and the incentives of the DRG prospective payment system. Acad Med. 1990;65:533–538
  18. Munoz E, Barrau L, Goldstein J, et al. DRG prospective, “all payor systems,” financial risk, and hospital cost in pulmonary medicine non CC stratified DRGs. Chest. 1988;94:855–861
  19. Shepard DS, Thompson MS. First principles of cost-effectiveness analysis in health. Public Health Rep. 1979;94:535–543
  20. Chandhoke PS, DeAntoni E. Cost-effectiveness analysis: application to endourology. J Endourol. 1998;12:485–491
  21. Henriksson P, Edhag O. Cost-effectiveness comparison of estrogen therapy and orchidectomy in patients with prostatic cancer. Int J Technol Assess Health Care. 1987;3:523–529
  22. Manca A, Sculpher MJ, Ward K, et al. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG. 2003;110:255–262
  23. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst. 1993;1585:1460–1474
  24. Saigal CS, Gornbein J, Nease R, et al. Predictors of utilities for health states in early stage prostate cancer. J Urol. 2001;166:942–946
  25. Saigal CS, Gornbein J, Reid K, et al. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Qual Life Res. 2002;11:405–414
  26. Nease RF, Owens DK. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making. 1994;14:382–392
  27. Albertsen PC, Nease RF, Potosky AL. Assessment of patient preferences among men with prostate cancer. J Urol. 1998;159:158–163
  28. Bennett CL, Greenfield S, Aronow H, et al. Patterns of care related to age of men with prostate cancer. Cancer. 1991;1567:2633–2641
  29. Joudi FN, Smith BJ, O'Donnell MA, et al. Contemporary management of superficial bladder cancer in the United States: A pattern of care analysis. Urology. 2003;62:1083–1088
  30. Bird VG, Fallon B, Winfield HN. Practice patterns in the treatment of large renal stones. J Endourol. 2003;17:355–363
  31. O'Leary MP, Gee WF, Holtgrewe HL, et al. 1999 American Urological Association Gallup Survey: Changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care. J Urol. 2000;164:1311–1316
  32. Fallon E, Ercole B, Lee C, et al. Contemporary management of ureteropelvic junction obstruction: practice patterns in Minnesota. J Endourol. 2005;19:41–44
  33. Wennberg JE, et al. Practice variations and health care reform: Connecting the dots. Health Aff (Millwood) Suppl Web Exclusive:VAR140-144. 2004;
  34. Weinstein JN, Bronner KK, Morgan TS, et al. Trends and geographic variations in major surgery for degenerative diseases of the hip, knee, and spine. Health Aff (Millwood) Suppl Web Exclusive VAR81-89. 2004;
  35. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending (Part 1: The content, quality, and accessibility of care). Ann Intern Med. 2003;18138:273–287
  36. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending (Part 2: Health outcomes and satisfaction with care). Ann Intern Med. 2003;18138:288–298
  37. Kramolowsky EV, Wood NL, Rollins KL, et al. The role of the physician in effecting change in hospital charge for radical prostatectomy. J Am Coll Surg. 1995;180:513–518
  38. Kramolowsky EV, Wood NL, Rollins KL, et al. Impact of physician awareness on hospital charges for radical retropubic prostatectomy. J Urol. 1995;154:139–142
  39. Sage WM, Kessler R, Sommers LS, et al. Physician-generated cost containment in transurethral prostatectomy. J Urol. 1988;140:311–315
  40. Cuckow PM. Cost of urology: Financial audit in a clinical department. BMJ. 1992;26305:743–746
  41. Cuckow PM. Costs can and must be a component of surgical audit. Ann R Coll Surg Engl. 1992;74:406–410discussion 410-411
  42. Forrest JB, Ritchie WP, Hudson M, et al. Cost containment through cost awareness: A strategy that failed. Surgery. 1981;90:154–158
  43. Carter GM, Melnick GA. How Services and Costs Vary by Day of Stay for Medicare Hospital Stays. Santa Monica, CA: The RAND Corporation; 1990;
  44. Haffer SC, Bowen SE. Measuring and improving health outcomes in Medicare: The Medicare HOS program. Health Care Financ Rev. 2004;25:1–3
  45. Holtgrewe HL. Managed care and its impact on American urology. Urology. 1998;51(suppl):31–35
  46. Holtgrewe HL. The economics of urologic practice in the twenty-first century. Urol Clin North Am. 1998;25:1–13
  47. Greenwald HP. HMO membership, copayment, and initiation of care for cancer: A study of working adults. Am J Public Health. 1987;77:461–466
  48. Greenwald HP, Henke CJ. HMO membership, treatment, and mortality risk among prostatic cancer patients. Am J Public Health. 1992;82:1099–1104
  49. Litwin MS, Saigal CS, Yano EM, et al. Urologic diseases in America Project: Analytical methods and principal findings. J Urol. 2005;173:933–937
  50. Williams RD. Urologic Diseases in America project. J Urol. 2005;173:679
  51. Iezzoni LI, Ash AS, Shwartz M, et al. Judging hospitals by severity-adjusted mortality rates: The influence of the severity-adjustment method. Am J Public Health. 1996;86:1379–1387
  52. Iezzoni LI. An introduction to risk adjustment. Am J Med Qual. 1996;11:S8–S11
  53. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–383
  54. Greenfield S, Apolone G, McNeil BJ, et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement Comorbidity and outcomes after hip replacement. Med Care. 1993;31:141–154
  55. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluation the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387–404
  56. Greenfield S, Sullivan L, Dukes KA, et al. Development and testing of a new measure of case mix for use in office practice. Med Care 3. 1995;(suppl):AS47–AS55
  57. Crabtree HL, Gray CS, Hildreth AJ, et al. The Comorbidity Symptom Scale: A combined disease inventory and assessment of symptom severity. J Am Geriatr Soc. 2000;48:1674–1678
  58. Di Gangi Herms AM, Pinggera GM, De Jonge P, et al. Assessing health care needs and clinical outcome with urological case complexity: A study using INTERMED. Psychosomatics. 2003;44:196–203
  59. Litwin MS, Greenfield S, Elkin EP, et al. Assessment of prognosis with the total illness burden index for prostate cancer: Aiding clinicians in treatment choice. Cancer. 2007;1109:1777–1783
  60. Albertsen PC, Fryback DG, Storer BE, et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996;156:127–132
  61. Bodenheimer T. High and rising health care costs (Part 1: Seeking an explanation). Ann Intern Med. 2005;17142:847–854
  62. Corrigan K, Ryan RH. New reimbursement models reward clinical excellence. Healthc Financ Manage. 2004;58:88–92
  63. Spencer BA, Steinberg M, Malin J, et al. Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol. 2003;21:1928–1936
  64. Litwin MS, Steinberg M, Malin JL, et al. Prostate Cancer Patient Outcomes and Choice of Providers: Development of an Infrastructure for Quality Assessment. Santa Monica, CA: The RAND Corporation; 2000;
  65. In:  Lohr KN editors. Medicare: A Strategy for Quality Assurance. Washington, DC: National Academy Press; 1990;
  66. Lohr KN, Donaldson MS, Harris-Wehling J. Medicare: A strategy for quality assurance, V: Quality of care in a changing health care environment. QRB Qual Rev Bull. 1992;18:120–126
  67. Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q. 1966;44(suppl):166–206
  68. Brook RH, McGlynn EA, Shekelle PG. Defining and measuring quality of care: A perspective from US researchers. Int J Qual Health Care. 2000;12:281–295
  69. Brook RH, McGlynn EA, Cleary PD. Quality of health care (Part 2: Measuring quality of care). N Engl J Med. 1996;335:966–970
  70. Brook RH, Kamberg CJ, Lohr KN, et al. Quality of ambulatory care (Epidemiology and comparison by insurance status and income). Med Care. 1990;28:392–433
  71. Nuttall M, van der Meulen J, Phillips N, et al. A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. J Urol. 2004;172:2145–2152
  72. Vitale MA, Arons RR, Hyman JE, et al. The contribution of hospital volume, payer status, and other factors on the surgical outcomes of scoliosis patients: A review of 3,606 cases in the State of California. J Pediatr Orthop. 2005;25:393–399
  73. Dibra A, Kastrati A, Schuhlen H, et al. The relationship between hospital or operator volume and outcomes of coronary patients undergoing percutaneous coronary interventions. Z Kardiol. 2005;94:231–238
  74. Killeen SD, O'Sullivan MJ, Coffey JC, et al. Provider volume and outcomes for oncological procedures. Br J Surg. 2005;92:389–402
  75. Lyman S, Jones EC, Bach PB, et al. The association between hospital volume and total shoulder arthroplasty outcomes. Clin Orthop Relat Res. 2005;432:132–137
  76. Lee KT, Chang WT, Huang MC, et al. Influence of surgeon volume on clinical and economic outcomes of laparoscopic cholecystectomy. Dig Surg. 2004;21:406–412
  77. Katz JN, Barrett J, Mahomed NN, et al. Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am. 2004;86A:1909–1916
  78. Joshi AV, Miller LA. Hospital procedure volume and outcomes. Ann Intern Med. 2004;140:1061–1062
  79. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346:1138–1144
  80. Hu JC, Gold KF, Pashos CL, et al. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol. 2003;21:401–405
  81. Ellison LM, Heaney JA, Birkmeyer JD. The effect of hospital volume on mortality and resource use after radical prostatectomy. J Urol. 2000;163:867–869
  82. Lu-Yao GL, Potosky AL, Albertsen PC, et al. Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. J Natl Cancer Inst. 1996;88:166–173
  83. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441–1445
  84. D'Amico AV, Moul J, Carroll PR, et al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol. 2005;173:1572–1576
  85. Schatzkin A, Freedman LS, Dorgan J, et al. Surrogate end points in cancer research: A critique. Cancer Epidemiol Biomarkers Prev. 1996;5:947–953
  86. Guyatt GH, Naylor CD, Juniper E, et al. Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. JAMA. 1997;16277:1232–1237
  87. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ. 1986;134:889–895
  88. Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology (Huntingt). 1995;9(suppl):47–60
  89. Strasser S, Aharony L, Greenberger D. The patient satisfaction process: Moving toward a comprehensive model. Med Care Rev. 1993;50:219–248
  90. Cleary PD, McNeil BJ. Patient satisfaction as an indicator of quality care. Inquiry. 1988;25:25–36
  91. Hayward RA, McMahon LF, Bernard AM. Evaluating the care of general medicine inpatients: How good is implicit review?. Ann Intern Med. 1993;1118:550–556
  92. Aharony L, Strasser S. Patient satisfaction: What we know about and what we still need to explore. Med Care Rev. 1993;50:49–79
  93. Williams G, Pazdur R, Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat. 2004;14:5–21
  94. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision-making. In:  Walker SR,  Rosser RM editor. Quality of Life Assessment: Key Issues in the 1990's. Dordrecht: Kluwer Academic Publishers; 1993;p. 11–64
  95. WHO. Constitution of the World Health Organization, Basic Documents. Geneva: WHO; 1948;
  96. Fossa SD. Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: Single institution experience. Br J Urol. 1994;74:345–351
  97. Litwin MS. Measuring health related quality of life in men with prostate cancer. J Urol. 1994;152:1882–1887
  98. Tulsky DS. An introduction to test theory. Oncology (Huntingt). 1990;4:43–48
  99. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;28334:835–840
  100. McSweeny AJ, Creer TL. Health-related quality-of-life assessment in medical care. Dis Mon. 1995;41:1–71
  101. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer. 1991;67(suppl):844–850
  102. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures (Statistics and strategies for evaluation). Control Clin Trials. 1991;12(suppl):142S–158S
  103. Adler NE, Epel ES, Castellazzo G, et al. Relationship of subjective and objective social status with psychological and physiological functioning: Preliminary data in healthy white women. Health Psychol. 2000;19:586–592
  104. Nelson EC, Landgraf JM, Hays RD, et al. The functional status of patients (How can it be measured in physicians' offices?). Med Care. 1990;28:1111–1126
  105. Finlay WM, Lyons E. Methodological issues in interviewing and using self-report questionnaires with people with mental retardation. Psychol Assess. 2001;13:319–335
  106. Fossa SD, Aaronson NK, Newling D, et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer (The EORTC Genito-Urinary Group). Eur J Cancer. 1990;26:1133–1136
  107. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol. 1998;159:1988–1992
  108. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient?. Br J Cancer. 1988;57:109–112
  109. Fossa SD, Moynihan C, Serbouti S. Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I (A descriptive pilot study). (see comments) Support Care Cancer. 1996;4:118–128
  110. Lampic C, von Essen L, Peterson VW, et al. Anxiety and depression in hospitalized patients with cancer: agreement in patient-staff dyads. Cancer Nurs. 1996;19:419–428
  111. Sneeuw KC, Aaronson NK, Sprangers MA, et al. Value of caregiver ratings in evaluating the quality of life of patients with cancer. J Clin Oncol. 1997;15:1206–1217
  112. Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review. J Clin Epidemiol. 1992;45:743–760
  113. Kornblith AB, Herr HW, Ofman US, et al. Quality of life of patients with prostate cancer and their spouses: The value of a data base in clinical care. Cancer. 1994;73:2791–2802
  114. Testa MA. Parallel perspectives on quality of life during antihypertensive therapy: Impact of responder, survey environment, and questionnaire structure. J Cardiovasc Pharmacol. 1993;21(suppl 2):S18–S25
  115. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27(suppl):S217–S232
  116. Fossa SD, Woehre H, Kurth KH, et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol. 1997;31(suppl):3–8
  117. McDowell I, Ewell C. Measuring health: A guide to rating scales and questionnaires. New York, NY: Oxford University Press; 1987;
  118. Ware JE, Kosinski M, Keller SK. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center; 1994;
  119. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) (I. Conceptual framework and item selection). Med Care. 1992;30:473–483
  120. Gandek B, Ware JE, Aaronson NK, et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: Results from the IQOLA Project.International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1149–1158
  121. Kaplan RM, Bush JW, Berry CC. Health status: Types of validity and the index of well-being. Health Serv Res. 1976;11:478–507
  122. Kaplan RM, Ganiats TG, Sieber WJ, et al. The Quality of Well-Being Scale: Critical similarities and differences with SF-36. Int J Qual Health Care. 1998;10:509–520
  123. Kaplan RM, Sieber WJ, Ganiats TG. The quality of well-being scale: comparison of the interviewer-administered version with a self-administered questionnaire. Psychol Health. 1997;12:783–791
  124. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol. 1982;1:61–80
  125. Kaplan RM, Anderson JP. A general health policy model: Update and applications. Health Serv Res. 1988;23:203–235
  126. Anderson JP, Kaplan RM, Berry CC, et al. Interday reliability of function assessment for a health status measure (The Quality of Well-Being scale). Med Care. 1989;27:1076–1083
  127. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: Development and final revision of a health status measure. Med Care. 1981;19:787–805
  128. Bergner M, Bobbitt RA, Pollard WE, et al. The sickness impact profile: Validation of a health status measure. Med Care. 1976;14:57–67
  129. Hunt SM, McEwen J, McKenna SP. Measuring health status: A new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985;35:185–188
  130. McDowell IW, Martini CJ, Waugh W. A method for self-assessment of disability before and after hip replacement operations. Br Med J. 1978;2:857–859
  131. Martini CJ, McDowell I. Health status: Patient and physician judgments. Health Serv Res. 1976;11:508–515
  132. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233
  133. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales. (ed 1). Boston, MA: The Health Institute, New England Medical Center; 1995;
  134. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project.International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171–1178
  135. Tannock IF. Management of breast and prostate cancer: How does quality of life enter the equation?. Oncology (Huntingt). 1990;4:149–156

PII: S1053-4296(08)00014-3

doi: 10.1016/j.semradonc.2008.01.002

Seminars in Radiation Oncology
Volume 18, Issue 3 , Pages 152-160 , July 2008

Article Tools